Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
brca1 Mutation Carrierbrca2 Mutation CarrierBreast CancerOvarian Cancer
Interventions
DRUG

rucaparib (CO-338; formally AG-014699 or PF-01367338)

GENETIC

protein expression analysis

GENETIC

western blotting

OTHER

immunohistochemistry staining method

OTHER

liquid chromatography

OTHER

mass spectrometry

OTHER

pharmacological study

Trial Locations (7)

B15 2TT

Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham

LS9 7TF

Leeds Cancer Centre at St. James's University Hospital, Leeds

W1T 4TJ

Cancer Research UK and University College London Cancer Trials Centre, London

M20 4BX

Christie Hospital, Manchester

NE4 6BE

Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Level 2, Freeman Hospital, Newcastle upon Tyne

PL6 8DH

Derriford Hospital, Plymouth

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cancer Research UK

OTHER